MGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Metagenomi Therapeutics Inc (MGX) is not a strong buy at this time for a beginner investor with a long-term focus. The lack of positive catalysts, weak financial performance, bearish technical indicators, and hedge fund selling trends suggest that the stock does not currently present a compelling investment opportunity.
The MACD is positive and expanding, indicating slight bullish momentum. However, the RSI is neutral, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 1.491, with resistance at 1.567 and support at 1.415. Overall, the technical indicators do not strongly support a buy signal.
No significant positive catalysts identified. MACD shows slight bullish momentum, and gross margin remains stable at 100%.
Hedge funds are selling heavily, with a 323.12% increase in selling over the last quarter. Financial performance shows a significant YoY revenue decline (-24.80%) and negative net income (-20.39M). No recent news or congress trading data is available to support the stock.
In Q3 2025, revenue dropped by 24.80% YoY to 8.659M. Net income improved slightly but remains negative at -20.39M (up 8.63% YoY). EPS improved to -0.55 (up 7.84% YoY). Gross margin is stable at 100%. Overall, financials indicate weak growth trends.
No recent analyst rating or price target changes are available for MGX.
